Trial Profile
A Phase Ib, Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Patients With Previously Treated Metastatic, Microsatellite-Stable Colorectal Adenocarcinoma With High CEACAM5 Expression
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Mar 2024
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Cibisatamab (Primary) ; Obinutuzumab (Primary) ; Tocilizumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Rectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 14 Mar 2024 Status changed from active, no longer recruiting to completed.
- 25 Oct 2023 Planned End Date changed from 31 Oct 2023 to 1 Mar 2024.
- 25 Oct 2023 Planned primary completion date changed from 31 Oct 2023 to 1 Mar 2024.